SEC Form 4 · accession 0001209191-18-020186
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara A Wood
Officer — EVP, Gen. Counsel, Corp. Sec.
Period of report
Mar 14, 2018
Accepted (ET)
Mar 16, 2018 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $5.10 | Mar 14, 2018 | A | 50,000 | A | — | Mar 13, 2028 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 14, 2018 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.